Search
for
Sort by
Research
660-690 / 1000+ resultsresearch Editorial Comment
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
research Prostatakarzinom
5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
research Beeinflussen Medikamente gegen das benigne Prostatasyndrom Stimmung oder Kognition?
Medications for benign prostatic syndrome can cause cognitive issues and depression.
research Focus sulla finasteride: efficacia, meccanismi e raccomandazioni per l'uso clinico
Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.
research Obstetrician/Gynecologist
I'm sorry, but there's not enough information to provide a summary.
research 710 BIOMARKERS OF SUNITNIB CLINICAL RESPONSE IN METASTATIC RENAL CLEAR CELL CARCINOMA PATIENTS
research Ovarian intratumoral 21-hydroxylase deficiency in a postmenopausal hirsute woman
A postmenopausal woman's masculine symptoms improved after surgery for a hormone-producing ovarian tumor.
research Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor
Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
research Predstanormix Duo – a new domestic combination drug for the treatment of lower urinary tract dysfunction symptoms associated with BPH.
Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.
research Detection of urine metabolites in polycystic ovary syndrome by UPLC triple-TOF-MS
Researchers found potential urine markers for polycystic ovary syndrome, including testosterone-glucuronide and 11α-hydroxyprogesterone, which may help diagnose the condition.
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
research S1 OPIOID RECEPTOR AGONISTS AND SERUM PROSTATE SPECIFIC ANTIGENE LEVEL: IS THERE A ROLE FOR PROSTATE CANCER CONTROL AND CHEMOPREVENTION?
Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
research Dutasteride/finasteride
research 174 Changes in urine androgen and PG levels during finasteride treatment
Finasteride treatment lowers urine androgen and prostaglandin levels, making them potential markers for effectiveness.
research Comparison of Clinical Efficacy of Finasteride and Dutasteride as 5-alpha Reductase Inhibitor
Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
research Efficacy, safety, and adverse effects of finasteride and dutasteride in treating benign prostatic hyperplasia: A retrospective cohort study
Finasteride and dutasteride are equally effective and safe for treating BPH.
research Investigation, treatment and monitoring of late‐onset hypogonadism in males: ISA, ISSAM, and EAU recommendations
Testosterone treatment for older men can have short-term benefits, but long-term risks are unclear, requiring careful evaluation and monitoring.
research Anti-BPH lignans from Urtica triangularis subsp. pinnatifida (Hand.-Mazz.) C.J.Chen
Lignans from Urtica triangularis may help treat benign prostatic hyperplasia (BPH).
research Relationship Between Serum Testosterone Levels and Kidney Stones Prevalence in Men
Lower testosterone levels increase kidney stone risk in men over 40.
research The effective course of finasteride pretreatment in decreasing blood loss associated with TURP
Taking finasteride for at least 3 months before TURP reduces blood loss.
research Erectile Dysfunction in Young Adults: A Narrative Review
Erectile dysfunction in young men is caused by both mental and physical factors and needs a personalized treatment approach.
research Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, and EAU Recommendations
Men with low testosterone should be carefully evaluated and monitored before and during treatment.
research Persistent Erectile Dysfunction after Discontinuation of 5-Alpha Reductase Inhibitor Therapy in Rats Depending on the Duration of Treatment
Long-term use of dutasteride can cause permanent erectile dysfunction in rats.
research New Drugs: Dutasteride
Dutasteride is approved to help manage prostate enlargement.
research An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
research Editorial Comment
Generic drugs for benign prostatic hyperplasia can cost up to 500% more at chain pharmacies compared to independent ones.
research PD59-09 PHOSPHODIESTERASE INHIBITORS COULD REVERSE THE PROLIFERATION OF BPH EPITHELIAL CELLS INDUCED BY CD8+ T CELLS IN LOW ANDROGEN CONDITION
Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
research Дослідження ПРОСПЕКТ IV (ПРОСтамол: ПЕрспективи Комбінованої Терапії) у хворих на доброякісну гіперплазію передміхурової залози
"Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.
research Association of long-term 5α-reductase inhibitor use with survival in men with renal cell carcinoma: a nationwide population-based cohort study
Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.